User:Mr. Ibrahem/Tavaborole

Mr. Ibrahem/Tavaborole
Clinical data
Trade names	Kerydin
Other names	AN2690
AHFS/Drugs.com	Monograph
MedlinePlus	a614049
Routes of; administration	Topical
Drug class	Antifungal
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-Fluoro-2,1-benzoxaborol-1(3H)-ol;
Chemical and physical data
Formula	C7H6BFO2
Molar mass	151.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1(C2=C(CO1)C=C(C=C2)F)O;
	InChI InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2; Key:LFQDNHWZDQTITF-UHFFFAOYSA-N;

Tavaborole, sold under the brand name Kerydin, is an antifungal medication used to treat fungal infections of the nail.^[1] It is used by applying it to the nail in question.^[1] Evidence supports its use in mild to moderate disease.^[2]

Side effects may include skin irritation and an ingrown toenail.^[1] It works by inhibits a enzyme, leucyl-tRNA synthetase, that is required for fungus to make protein.^[1]

Tavaborole was approved for medical use in the United States in 2014.^[3] In the United States 10 ml of solution costs about 1,600 USD as of 2021.^[4] It is also available in Canada but not in Europe as of 2018.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g "Tavaborole Monograph for Professionals". Drugs.com. Archived from the original on 21 May 2016. Retrieved 23 September 2021.
^ Jinna, S; Finch, J (2015). "Spotlight on tavaborole for the treatment of onychomycosis". Drug design, development and therapy. 9: 6185–90. doi:10.2147/DDDT.S81944. PMID 26640371.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Gupta, Aditya K.; Mays, Rachel R.; Folley, Kelly A. (2019). "42. Topical antifungal agents". In Wolverton, Stephen E.; Wu, Jashin J. (eds.). Comprehensive Dermatologic Drug Therapy (4th ed.). Elsevier. p. 488. ISBN 978-0-323-61211-1. Archived from the original on 2021-10-09. Retrieved 2021-10-07.
^ "Kerydin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 15 January 2021. Retrieved 23 September 2021.
^ Rigopoulos, Dimitris; Elewski, Boni; Richert, Bertrand (6 August 2018). Onychomycosis: Diagnosis and Effective Management. John Wiley & Sons. p. 105. ISBN 978-1-119-22653-6. Archived from the original on 23 September 2021. Retrieved 23 September 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g "Tavaborole Monograph for Professionals". Drugs.com. Archived from the original on 21 May 2016. Retrieved 23 September 2021.

[2] Jinna, S; Finch, J (2015). "Spotlight on tavaborole for the treatment of onychomycosis". Drug design, development and therapy. 9: 6185–90. doi:10.2147/DDDT.S81944. PMID 26640371.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[Wolverton2019-3] Gupta, Aditya K.; Mays, Rachel R.; Folley, Kelly A. (2019). "42. Topical antifungal agents". In Wolverton, Stephen E.; Wu, Jashin J. (eds.). Comprehensive Dermatologic Drug Therapy (4th ed.). Elsevier. p. 488. ISBN 978-0-323-61211-1. Archived from the original on 2021-10-09. Retrieved 2021-10-07.

[4] "Kerydin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 15 January 2021. Retrieved 23 September 2021.

[5] Rigopoulos, Dimitris; Elewski, Boni; Richert, Bertrand (6 August 2018). Onychomycosis: Diagnosis and Effective Management. John Wiley & Sons. p. 105. ISBN 978-1-119-22653-6. Archived from the original on 23 September 2021. Retrieved 23 September 2021.

[1]

[2]

[3]

[4]

[5]